Prodia Diagnostic Line Tbk vs Sinarmas Multiartha Tbk. — how do they compare? Prodia Diagnostic Line Tbk trades at Rp236 (market cap 428.75B, 13.83M 24h volume), while Sinarmas Multiartha Tbk. trades at Rp20,025 (market cap 127.51T, 300 24h volume). The key difference: Sinarmas Multiartha Tbk. is far larger — about 297.4× Prodia Diagnostic Line Tbk's market cap, and Prodia Diagnostic Line Tbk is more actively traded (13.83M versus 300). Which is the better fit depends on your goals.
| PRDL | SMMA | |
|---|---|---|
Market Cap | 428.75B | 127.51T |
Volume | 13.83M | 300 |
Lot | 138.27K | 3 |
Turnover | 3.27B | 6M |
Average Price | 236.62 | 20,008.33 |
Value | 3.27B | 6M |
Indicative Equilibrium Price | 236 | — |
Indicative Equilibrium Volume | 1.74K | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →PT Sinar Mas Multiartha Tbk was established by Deed No. 60 dated October 21, 1982 from Benny Kristianto, S.H., notary in Jakarta. PT Sinar Mas Multiartha was initially active in commercial leasing, consumer financing and venture capital, and purely became a holding company in the Sinar Mas Group.
Read more on SMMA →